Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Turcot syndrome 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Brain Neoplasms 1

Interventions

Temozolomide 3Specimen Handling 2tovorafenib 1spartalizumab 1ribociclib 1pembrolizumab 1lutetium Lu 177 dotatate 1larotrectinib 1balstilimab 1Vaccines 1Receptors, Interleukin-8B 1Radiotherapy 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1PTC596 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Injections 1Immune Checkpoint Inhibitors 1Fluid Therapy 1Everolimus 1Eflornithine 1Diphtheria-Tetanus Vaccine 1Diffusion Tensor Imaging 1Cilengitide 1CLR1404 1CBLC137 1Biopsy 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × Diffusion Tensor Imaging × 90 days × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡